MX2022002571A - Terapia enzimatica con cistationina beta-sintasa para el tratamiento de niveles elevados de homocisteina. - Google Patents
Terapia enzimatica con cistationina beta-sintasa para el tratamiento de niveles elevados de homocisteina.Info
- Publication number
- MX2022002571A MX2022002571A MX2022002571A MX2022002571A MX2022002571A MX 2022002571 A MX2022002571 A MX 2022002571A MX 2022002571 A MX2022002571 A MX 2022002571A MX 2022002571 A MX2022002571 A MX 2022002571A MX 2022002571 A MX2022002571 A MX 2022002571A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- treatment
- homocysteine levels
- synthase enzyme
- elevated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
- C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
- G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
Abstract
La presente divulgación proporciona métodos para tratar la homocistinuria o niveles elevados de homocisteína en sujetos, incluidos métodos para mejorar la función cognitiva y mejorar la fragilidad esquelética, y métodos para estratificar poblaciones de pacientes para determinar la progresión o gravedad de la enfermedad y/o para determinar regímenes de tratamiento.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962895230P | 2019-09-03 | 2019-09-03 | |
US202062983862P | 2020-03-02 | 2020-03-02 | |
PCT/US2020/049156 WO2021046190A1 (en) | 2019-09-03 | 2020-09-03 | Cystathionine beta-synthase enzyme therapy for treatment of elevated homocysteine levels |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022002571A true MX2022002571A (es) | 2022-05-06 |
Family
ID=74852233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022002571A MX2022002571A (es) | 2019-09-03 | 2020-09-03 | Terapia enzimatica con cistationina beta-sintasa para el tratamiento de niveles elevados de homocisteina. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220290116A1 (es) |
EP (1) | EP4025243A4 (es) |
JP (1) | JP2022546550A (es) |
KR (1) | KR20220091464A (es) |
CN (1) | CN114630673A (es) |
AU (1) | AU2020343314A1 (es) |
BR (1) | BR112022003539A2 (es) |
CA (1) | CA3152379A1 (es) |
IL (1) | IL290685A (es) |
MX (1) | MX2022002571A (es) |
WO (1) | WO2021046190A1 (es) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9675678B2 (en) * | 2013-01-29 | 2017-06-13 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treatment of homocystinuria |
CN118064414A (zh) * | 2017-04-17 | 2024-05-24 | 科罗拉多州立大学董事会法人团体 | 治疗同型半胱氨酸尿症的酶替代疗法优化 |
BR112021026292A2 (pt) * | 2019-06-26 | 2022-05-31 | Univ Colorado Regents | Cistationina beta sintase peguilada para terapia enzimática para tratamento de homocistinúria |
-
2020
- 2020-09-03 CN CN202080076522.3A patent/CN114630673A/zh active Pending
- 2020-09-03 KR KR1020227011039A patent/KR20220091464A/ko unknown
- 2020-09-03 MX MX2022002571A patent/MX2022002571A/es unknown
- 2020-09-03 AU AU2020343314A patent/AU2020343314A1/en active Pending
- 2020-09-03 WO PCT/US2020/049156 patent/WO2021046190A1/en active Application Filing
- 2020-09-03 US US17/639,509 patent/US20220290116A1/en active Pending
- 2020-09-03 EP EP20861108.7A patent/EP4025243A4/en active Pending
- 2020-09-03 CA CA3152379A patent/CA3152379A1/en active Pending
- 2020-09-03 JP JP2022514172A patent/JP2022546550A/ja active Pending
- 2020-09-03 BR BR112022003539A patent/BR112022003539A2/pt unknown
-
2022
- 2022-02-17 IL IL290685A patent/IL290685A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN114630673A (zh) | 2022-06-14 |
AU2020343314A1 (en) | 2022-03-24 |
US20220290116A1 (en) | 2022-09-15 |
KR20220091464A (ko) | 2022-06-30 |
EP4025243A4 (en) | 2023-09-27 |
EP4025243A1 (en) | 2022-07-13 |
JP2022546550A (ja) | 2022-11-04 |
WO2021046190A1 (en) | 2021-03-11 |
IL290685A (en) | 2022-04-01 |
CA3152379A1 (en) | 2021-03-11 |
BR112022003539A2 (pt) | 2022-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019001353A1 (es) | Compuestos con actividad antitumoral contra células cancerígenas que portan mutaciones en el exón 20 de egfr o her2. | |
PH12017502154A1 (en) | Methods for conditioning patients for t cell therapy | |
WO2016201450A3 (en) | Cancer treatment and diagnosis | |
CL2018001677A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
MY191040A (en) | Therapy involving antibodies against claudin 18.2 for treatment of cancer | |
MX2018001435A (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
MX2019014410A (es) | Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
MX2018004170A (es) | Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos. | |
EP3712264A8 (en) | Cystathionine beta-synthase enzyme for treatment of homocystinuria | |
EA201491584A1 (ru) | Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor | |
PH12020551597A1 (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
MD3347002T2 (ro) | Tratamentul bolii Alzheimer într-o populație specifică de pacienți | |
EA201790563A8 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
GB201202561D0 (en) | Treatment of skin disorders | |
EA201591522A1 (ru) | Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов | |
MX2022002571A (es) | Terapia enzimatica con cistationina beta-sintasa para el tratamiento de niveles elevados de homocisteina. | |
MX2015016844A (es) | Marcador para trastornos de la esfingomielinasa acida y sus usos. | |
MX2022016061A (es) | Degradadores de cinasa asociada al receptor interleucina-1 (irak) y usos de los mismos. | |
MX2021009247A (es) | Metodos, sistemas y kits para tratar enfermedades inflamatorias que se dirigen a il18r1. | |
MX2015008190A (es) | Tretaspanina 33 es una candidata para la terapia dirigida de anticuerpos para el tratamiento de linfomas de hodgkin de linfocitos b. | |
AU2016303622A8 (en) | Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor | |
MX2023003258A (es) | Tratamiento de enfermedades mediadas por nf-kb. | |
PH12021551137A1 (en) | Application of chidamide | |
MX2021009326A (es) | Pridopidina de dosis baja para mal de parkinson y otras enfermedades asociadas con parkinsonismo. | |
MX2020001217A (es) | Metodos de tratamiento de sintomas de gastroparesia usando velusetrag. |